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Abstract
Nitric oxide synthase 3 (NOS3) catalyzes production of NO in the endothelium and may play a role in cardiovascular disease
(CVD). We assessed the pharmacogenetic associations of three NOS3 polymorphisms and three antihypertensive drugs with
CVD outcomes. Hypertensive subjects (n=30,280) from a multi-center, double-blind clinical trial were randomized to
chlorthalidone, amlodipine, or lisinopril treatment (mean follow up, 4.9 years). Outcomes included coronary heart disease
(CHD: fatal CHD and nonfatal myocardial infarction); stroke; heart failure (fatal, requiring hospitalization, or outpatient
treatment); all-cause mortality; and end-stage renal disease (ESRD). Main effects of NOS3 variants on outcome and
genotype-treatment interactions were tested. For NOS3 2690 C.T (rs3918226), a higher hazard ratio (HR) was found in
minor allele carriers for CHD (CC=1.00, CT+TT=1.12 (95% confidence interval (CI)=1.00–1.26), P=0.048). For NOS3 2922
A.G (rs1800779), a higher HR was found in minor allele carriers for heart failure (AA=1.00, AG+GG=1.10 (CI=1.00–1.21),
P=0.046). Significant pharmacogenetic findings were observed for stroke and all-cause mortality. For 2690 C.T, a lower HR
was observed for stroke in minor allele carriers when treated with amlodipine versus lisinopril (CC=0.85 (CI=0.73–0.99),
CT+TT=0.49 (CI=0.31–0.80), P=0.04). For glu298asp G.T (rs1799983), a lower HR was observed for all-cause mortality in
minor allele carriers when treated with amlodipine versus lisinopril (GG=1.01 (CI=0.91–1.13), GT+TT=0.85 (CI=0.75–0.97),
P=0.04). We observed significant associations with NOS3 variants and CHD and heart failure and significant
pharmacogenetic effects for stroke and all cause mortality. This suggests that NOS3 variants may potentially provide
useful clinical information with respect to treatment decisions in the future.
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Introduction
Hypertension is a major risk factor for cardiovascular disease
(CVD), a leading cause of mortality worldwide. Control of
hypertension is an important priority [1]. Despite improved
treatment options, one-third of treated hypertensive patients have
blood pressure above target thresholds [2]. One reason for this is
that individual response to pharmacologic treatments varies;
genetics may be an important determinant of this variable
response. Evidence increasingly suggests genetic polymorphisms
interact with antihypertensive treatments leading to different blood
pressure responses and cardiovascular outcomes [3].
Given nitric oxide’s (NO) role in regulating vascular function,
the nitric oxide synthase 3 (endothelial cell) gene (NOS3) may play
a role in cardiovascular pathology and individual responses to
antihypertensive drugs [4]. NOS3 catalyzes the production of
biological NO, a critical signaling molecule in the relaxation of
vascular smooth muscle and vasodilatation. Reduction in basal
NO release may predispose humans to hypertension, thrombosis,
vasospasm, and atherosclerosis [5]. Conversely, overproduction of
NO can also damage cells and tissues. Alteration in NO level can
be caused by DNA variants that impair the function of NOS3.
Many reports have indicated association of NOS3 polymorphisms
with increased occurrence of cardiovascular disease, including
coronary artery disease [6,7,8,9], myocardial infarction [10,11],
hypertension [12,13], and stroke [14]. Despite its pharmacoge-
netic potential, there are few data regarding the impact of NOS3
variants on the drug responses in hypertension treatments.
Amlodipine is a widely prescribed antihypertensive drug. As a
calcium channel blocker, amlodipine inhibits the influx of calcium
into smooth muscle cells, which is thought to be the major
mechanism leading to vasorelaxation. Amlodipine also causes
vasodilatation through the activation of NOS3 and subsequent
production of NO [15]. Moreover, one of the pathways in NOS3
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34217activation is calcium dependent. This evidence suggests a
mechanism of amlodipine action through NOS3.
In the present study, we tested whether participants in the
Genetics of Hypertension Associated Treatment (GenHAT) Study
with different NOS3 genotypes randomized to amlodipine treat-
ment had different outcomes with regard to five CVD measures
than their counterparts who were randomized to lisinopril or
chlorthalidone. We sought to determine whether there was a
detectable pharmacogenetic association of NOS3 variants with
CVD among those randomized to one of these three antihyper-
tensive medications.
Methods
Ethics Statement
Participants recruited during the parent Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT) signed informed consent documents; the GenHAT
study was approved by the University of Minnesota Institutional
Review Board, the University of Alabama at Birmingham
Institutional Review Board for Human Use, and the University
of Texas Health Science Center at Houston Committee for the
Protection of Human Subjects.
Study Population
The GenHAT study is ancillary to the Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). The GenHAT population has been previously
described [16]. The present study is a subgroup analysis from
GenHAT in which 30,280 participants with known genotypes of
NOS3 were analyzed. Approximately half of the participants were
women (47%), and 61% of the participants were white.
Participants with missing genotypes were excluded from the
analysis; therefore, there were 30,269, 30,239 and 30,240
participants included in the analyses for NOS3 2690 C.T
(rs3918226), NOS3 2922 A.G (1800779) and NOS3 glu298asp
G.T (rs1799983), respectively.
Outcome Ascertainment
Outcomes of interest in this analysis were coronary heart disease
(CHD), including fatal CHD and nonfatal myocardial infarction;
stroke; heart failure (fatal, requiring hospitalization, or treated in
an outpatient setting); all-cause mortality; and end stage renal
disease. Outcomes were reported by clinical investigators. For
outcomes involving death, documentation was obtained from
death certificates and national databases to identify deaths among
participants lost to follow-up. A detailed outcome ascertainment
for ALLHAT has been previously published [17].
Genotyping
DNA samples were collected on FTA paper (Fitzco Inc., Maple
Plain, MN) and processed as previously described [18]. A multiplex
PCR and immobilized probe-based research assay (Roche Molec-
ular Systems, Pleasanton, CA, USA) [19] was used to genotype the
three single-nucleotide polymorphisms (SNPs) listed above. Al-
thoughtheSNPs used intheseanalyseswere chosenbecause of their
availability in the Roche genotyping assay, the variants chosen by
Roche were selected on the basis of disease association and
functional data available at the time of the assay’s design; there is
evidence of association with cardiovascular disease in various ethnic
and other subgroups for each of the variants [20,21,22]. The
pairwise linkage disequilibrium R
2 values for the 3 SNPs in the
1000 Genomes CEU population are rs3918226-rs1800779: 0.132;
rs3918226-rs1799983: 0.092; rs1800779- rs1799983: 0.137. R
2s
were considerably lower in other race groups.
Statistical Analysis
Statistical Analysis Software (SAS), version 9.1 (SAS Institute
Inc., Cary, NC) was used for statistical analysis. Hardy-Weinberg
(HW) equilibrium tests were performed using chi-square tests. Cox
regression was used to test the main effects of NOS3 genotypes and
genotype6treatment interactions on clinical outcomes, resulting in
hazard ratios (HRs). In each of the NOS3 genotypes, the outcomes
from amlodipine-treated patients were compared with those from
patients treated with chlorthalidone and lisinopril using Cox
regression. The main effects of genotypes on outcomes were
assessed without or with adjustments for treatment, age, sex, race,
Hispanic status, baseline body mass index, diabetes status, baseline
total cholesterol, smoking status, and baseline systolic and diastolic
blood pressures. The previously published GenHAT design paper
[23] outlined six primary, a priori hypotheses; however, these
hypotheses did not include testing the pharmacogenetic effect of
NOS3 variants. Therefore, secondary investigations such as this
study are considered exploratory and, as such, are not adjusted for
multiple comparisons. Since we performed multiple statistical tests
of the pharmacogenetic effects of NOS3 variants, caution must be
exercised in interpreting these findings.
Results
Baseline characteristics for the 30,280 participants are shown in
Table 1. No differences were found in baseline values among
treatment groups.
Hardy-Weinberg equilibrium was tested in each race group.
NOS3 2690 C.T genotype frequencies were in HW equilibrium in
all the race groups. NOS3 2922 A.G genotype frequencies were in
HW equilibrium in white, black, American Indian/Alaskan native,
and Asian/Pacific islander, but not in the ‘‘other race’’ group
(P=0.045). NOS3 glu298asp G.T genotype frequencies were in
HW equilibrium in all the groups except whites (P=0.0088).
Main Effect of NOS3 Variants on Clinical Outcomes
Hazard ratios for main effects of the NOS3 variants on clinical
outcomes are summarized in Table 2. No association of NOS3
variants with any clinical outcome was detected when genotypes
were analyzed individually (data not shown). When minor allele
carriers were combined (CT and CC for NOS3 2690 C.T, AG
and GG for NOS3 2922 A.G, GT and TT for NOS3 glu298asp
G.T), associations were found in the adjusted models between
NOS3 2690 C.T and CHD, and NOS3 2922 A.G and heart
failure (p,0.05). Minor allele carriers of NOS3 2690 C.T have
higher risk of CHD (HR, 1.12; 95% CI, 1.00–1.26) and minor
allele carriers of NOS3 2922 A.G have higher risk to heart failure
(HR, 1.10; 95% CI, 1.00–1.21 compared to their respective wild-
type homozygous individuals.
Pharmacogenetic Association (Genotype6Treatment
Interactions) with Clinical Outcomes
Table 3 summarizes outcome frequencies and rates by genotype
group, genotype-specific treatment effects, and the results of
pharmacogenetic association tests for amlodipine versus chlorthal-
idone and amlodipine versus lisinopril. For pharmacogenetic tests,
a significant P value for the genotype6treatment interaction
indicates that the treatment effects differ by genotypes.
Our data suggested a pharmacogenetic association for the
2690 C.T variant with stroke, and for the glu298asp G.T with
all-cause mortality when comparing amlodipine with lisinopril.
NOS3 Cardiovascular Disease Pharmacogenetics
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carriers at the NOS3 2690 locus showed lower risk of stroke (HR,
0.49 vs. 0.85; 95% CI, 0.31–0.80 vs. 0.73–0.99; P=0.04), and the
minor allele carriers at the glu298asp locus showed lower risk of
all-cause mortality (HR, 0.85 vs. 1.01; 95% CI, 0.75–0.97 vs.
0.91–1.13, P=0.04) compared to their respective wild type
homozygous individuals.
Discussion
NO is a critical signaling molecule in many physiological and
pathological processes. Three NO synthase (NOS) enzymes have
been identified, which catalyze the production of biological NO
from L-arginine. Primarily expressed in endothelia, the NOS3
enzyme has been proposed to be the most relevant NOS in
Table 1. Baseline characteristics for participants (n=30,280) by treatment group.
Characteristic Amlodipine Lisinopril Chlorthalidone P value*
Sample size, n (%) by treatment 8,178 (27.0) 8,237 (27.2) 13,865 (45.8)
Age (y), mean (SD) 66.9 (7.7) 66.8 (7.8) 66.8 (7.7) 0.92
Race:
White, n (%) 4,955 (60.6) 5,000 (60.7) 8,424 (60.8) 0.85
Black, n (%) 2,834 (34.7) 2,828 (34.3) 4,741 (34.2)
American Indian/Alaskan native, n (%) 19 (0.2) 18 (0.2) 27 (0.2)
Asian/Pacific Islander, n (%) 96 (1.2) 85 (1.0) 169 (1.2)
Other, n (%) 274 (3.4) 306 (3.7) 504 (3.6)
Hispanic, n (%) 1,554 (19.0) 1,631 (19.8) 2,704 (19.5) 0.75
Women, n (%) 3,891 (47.6) 3,819 (46.4) 6,518 (47.0) 0.30
On antihypertensive treatment, n (%) 7,409 (90.6) 7,418 (90.1) 12,510 (90.2) 0.49
Blood pressure at baseline:
All participants, mm Hg: SBP, mean (SD) 146.2 (15.7) 146.6 (15.6) 146.2 (15.7) 0.25
DBP, mean (SD) 83.9 (10.2) 84.1 (10.0) 84.1 (10.1) 0.20
Treated at baseline, mm Hg: SBP, mean (SD) 145.1 (15.6) 145.5 (15.5) 145.2 (15.7) 0.74
DBP, mean (SD) 83.3 (10.1) 83.6 (9.9) 83.5 (10.0) 0.32
Untreated at baseline, mm Hg: SBP, mean (SD) 156.5 (12.1) 156.4 (12.4) 156.1 (12.0) 0.68
DBP, mean (SD) 89.7 (9.6) 89.1 (9.3) 89.5 (9.0) 0.42
Eligibility risk factors:
Current cigarette smoker, n (%) 1,805 (22.1) 1,803 (21.9) 3,056 (22.0) 0.95
Type 2 diabetes, n (%) 2,976 (36.4) 2,886 (35.0) 4,964 (35.8) 0.19
HDL-C,35 mg/dL, n (%) 932 (11.4) 965 (11.7) 1,661 (12.0) 0.43
LVH by electrocardiogram, n (%) 1,398 (17.1) 1,333 (16.2) 2,236 (16.1) 0.14
BMI, mean (SD) 29.8 (6.3) 29.8 (6.2) 29.7 (6.1) 0.44
Fasting glucose, mean (SD), mg/dL 122.9 (57.3) 122.4 (55.8) 123.3 (58.5) 0.63
Total cholesterol, mean (SD), mg/dL 216.8 (43.9) 215.6 (42.2) 216.2 (43.5) 0.25
HDL cholesterol, mean (SD), mg/dL 47.2 (14.7) 46.6 (14.6) 46.8 (14.9) 0.05
Fasting triglycerides, mean (SD), mg/dL 176.8 (133.0) 175.6 (138.9) 177.0 (132.5) 0.74
Serum creatinine, mean (SD), mg/dL 1.01 (0.30) 1.02 (0.29) 1.02 (0.31) 0.04
NOS3 2690 C.T, n (%)
CC 7,244 (88.6) 7,293 (88.6) 12,306 (88.8) 0.32
CT 897 (11.0) 905 (11.0) 1,477 (10.7)
TT 32 (0.4) 36 (0.4) 79 (0.6)
NOS3 2922 A.G, n (%)
AA 4,169 (51.1) 4,239 (51.5) 6,990 (50.5) 0.40
AG 3,202 (39.3) 3,204 (38.9) 5,566 (40.2)
GG 786 (9.6) 787 (9.6) 1,296 (9.4)
NOS3 glu298asp G.T, n (%)
GG 4,791 (58.6) 4,773 (58.0) 8,042 (58.1) 0.16
GT 2,761 (33.8) 2,852 (34.7) 4,853 (35.1)
TT 619 (7.6) 599 (7.3) 950 (6.9)
*test of differences between treatment groups: ANOVA for continuous variables, chi-square for categorical variables. DBP, diastolic blood pressure; HDL-C, HDL
cholesterol; LVH, left ventricular hypertrophy; SBP, systolic blood pressure.
doi:10.1371/journal.pone.0034217.t001
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been reported since the cloning of NOS3; variations may result in
reduced or excessive production of NO and contribute to
cardiovascular diseases [24]. In the present study, we examined
the association of the NOS3 variants 2690 C.T, 2922 A.G, and
glu298asp G.T with five CVD outcomes. Association was
detected between 2690 C.T and CHD, 2922 A.G and heart
failure. We also compared the pharmacogenetic effects in
amlodipine group versus lisinopril and chlorthalidone groups.
Our data suggest that minor allele carriers for 2690 C.T and
glu298asp G.T may have lower risk of stroke and all-cause
mortality when using amlodipine as compared to lisinopril.
As one of the polymorphisms in the coding region of NOS3, the
glu298asp G.T variant has been studied extensively. This G-to-T
transversion at nucleotide position 894 within exon 7 results in a
change of glutamate to aspartate at position 298 in the oxygenase
domain of the NOS3 protein. Associations between the glu298asp
G.T polymorphism and NO synthesis [25,26] and endothelial
function [27,28] have been previously described. The change of
glutamate to aspartate may affect the interaction of NOS3 with
caveolin-1, thereby affecting the localization of NOS3 and,
eventually, diminishing the activation of NOS3 [29]. Molecular
studies suggested that, even though intact NOS3 Asp298 has
equivalent enzymatic activity to NOS3 Glu298, carriers of NOS3
Asp298 may be at different disease risk if exposed to adverse
environmental influence on endothelial function [30]. Epidemio-
logic studies have associated this polymorphism with the
development of hypertension [31], CHD, and endothelial
dysfunction [28]. Glu298asp G.T may also play a role in renal
function. GG carriers were reported to have lower mean arterial
pressure and an augmented glomerular filtration rate than the
homozygotes for the wild type allele [32]. In response to a graded
L-arginine infusion, the GG carriers had significant changes in
effective renal plasma flow, glomerular filtration rate, filtration
fraction, renal vascular resistance, and renal blood flow. In
contrast, the renal response to L-arginine in GT/TT carriers was
blunted. Epidemiologic studies, however, reported inconsistent
results on the association between glu298asp and end-stage renal
disease. This may be partly due to different cohorts chosen in
different studies. Although several studies suggested the T allele is
the risk allele for end-stage renal disease [33,34,35,36], others
reported that homozygosity for the G allele was associated with
increased risk with diabetic nephropathy [37], or showed no
association with ESRD [38]. Our study did not find statistical
Table 2. Main effects of NOS3 variants on outcomes, event frequencies and rates, hazard ratios.
NOS3 2690 C.T NOS3 2922 A.G NOS3 glu298asp G.T
Outcome
CC
(n=26,843)
CT+TT
(n=3,426) P value
AA
(n=15,398)
AG+GG
(n=14,841) P value
GG
(n=17,606)
GT+TT
(n=12,634) P value
CHD (primary endpoint)
Event frequency 2325 354 1326 1350 1513 1163
Event rate* 18.8 22.7 18.7 19.8 18.7 20.1
Unadjusted HR (95% CI) 1.00 1.20 (1.08–1.34) 0.001 1.00 1.06 (0.98–1.14) 0.15 1.00 1.07 (0.99–1.16) 0.07
Adjusted HR
{ (95% CI) 1.00 1.12 (1.00–1.26) 0.048 1.00 0.98 (0.90–1.06) 0.62 1.00 1.00 (0.92–1.08) 0.94
Stroke
Event frequency 1218 139 720 638 826 531
Event rate* 9.8 8.7 10.1 9.2 10.1 9.0
Unadjusted HR (95% CI) 1.00 0.89 (0.75–1.06) 0.20 1.00 0.92 (0.82–1.02) 0.11 1.00 0.89 (0.80–0.99) 0.04
Adjusted HR
{ (95% CI) 1.00 0.96 (0.80–1.15) 0.63 1.00 0.97 (0.86–1.09) 0.58 1.00 0.95 (0.84–1.07) 0.38
Heart failure
Event frequency 1769 243 970 1041 1176 833
Event rate* 14.3 15.4 13.7 15.3 14.5 14.3
Unadjusted HR (95% CI) 1.00 1.08 (0.94–1.23) 0.27 1.00 1.12 (1.02–1.22) 0.01 1.00 0.99 (0.90–1.08) 0.75
Adjusted HR
{ (95% CI) 1.00 1.04 (0.90–1.19) 0.63 1.00 1.10 (1.00–1.21) 0.046 1.00 0.94 (0.85–1.03) 0.20
All-cause mortality
Event frequency 3761 498 2183 2069 2527 1728
Event rate* 28.6 29.7 28.9 28.5 29.3 27.9
Unadjusted HR (95% CI) 1.00 1.04 (0.95–1.14) 0.42 1.00 0.99 (0.93–1.05) 0.64 1.00 0.96 (0.90–1.02) 0.16
Adjusted HR
{ (95% CI) 1.00 1.05 (0.95–1.15) 0.37 1.00 0.99 (0.93–1.05) 0.72 1.00 0.97 (0.91–1.03) 0.32
End-stage renal disease
Event frequency 366 30 214 181 264 131
Event rate* 2.9 1.9 2.9 2.6 3.2 2.2
Unadjusted HR (95% CI) 1.00 0.64 (0.44–0.93) 0.02 1.00 0.88 (0.72–1.07) 0.19 1.00 0.69 (0.56–0.85) 0.0005
Adjusted HR
{ (95% CI) 1.00 0.84 (0.57–1.23) 0.36 1.00 1.09 (0.98–1.35) 0.44 1.00 0.84 (0.67–1.06) 0.14
*per 1000 person-year.
{adjusted for treatment, age, sex, race, Hispanic status, baseline BMI, diabetes status, baseline total cholesterol, smoking status, baseline systolic and diastolic blood
pressures. CHD, coronary heart disease (including fatal CHD and nonfatal myocardial infarction); CI, confidence interval; HR, hazard ratio.
doi:10.1371/journal.pone.0034217.t002
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stage renal disease in hypertensive patients.
Variations in the promoter regions of NOS3 have also been
identified, among which are 2922A/G and 2690C/T. Although
these variations are not located in the catalytic site or consensus
sequences for transcription factor binding [24,39], they may affect
the protein level and enzyme activity through regulation of gene
expression, thereby affecting the plasma NO metabolite levels
[40], blood pressure, and risk of cardiovascular diseases. A recent
genome-wide association study of essential hypertension singled
out 2690 C.T as potentially playing a role in hypertension. Not
only were hypertension associations with the polymorphism
genome-wide significant in a 2-stage case-control study, the
finding was confirmed in a 21,714-subject meta-analysis. Using
PATCH, the authors identified a putative binding site for ETS
family transcription factors directly next to the 2690 C.T locus.
ETS-1 and ELF-1 are essential factors for activation of the NOS3
promoter, suggesting that this variant might modulate the
transcription of NOS3 [41]. Our study showed that minor allele
carriers for 2690 C.T have higher risk in CHD, and minor allele
Table 3. Genotype6treatment interaction results, total events and event rates by genotype and treatment group.
Number of events, event rates
per 1000 person-years
Genotype-specific treatment effect
hazard ratio (95%CI)
Genotype-by-
treatment
interaction P values*
Outcome - Variant Genotype AML LIS CHL AML vs. LIS AML vs. CHL
AML vs.
LIS
AML vs.
CHL
CHD (primary outcome)
2690 C.T CC 642, 19.2 618, 18.6 1065, 18.8 1.03 (0.92–1.15) 1.02 (0.92–1.12)
CT+TT 89, 20.8 90, 21.2 175, 24.6 0.98(0.73–1.32) 0.85(0.66–1.09) 0.77 0.19
2922 A.G AA 377, 19.6 345, 17.8 604, 18.8 1.10 (0.95–1.27) 1.04 (0.91–1.18)
AG+GG 352, 19.1 363, 20.0 635, 20.1 0.95 (0.82–1.10) 0.95 (0.83–1.08) 0.17 0.34
glu298asp G.T GG 428, 19.3 384, 17.6 701, 19.0 1.10 (0.96–1.26) 1.02 (0.90–1.15)
GT+TT 303, 19.4 323, 20.6 537, 20.1 0.94 (0.81–1.10) 0.97 (0.84–1.11) 0.16 0.60
Stroke
2690 C.T CC 310, 9.1 361, 10.7 547, 9.5 0.85 (0.73–0.99) 0.96 (0.83–1.10)
CT+TT 25, 5.7 50, 11.6 64, 8.7 0.49 (0.31–0.80) 0.66 (0.42–1.05) 0.04 0.13
2922 A.G AA 172, 8.8 221, 11.3 327, 10.1 0.78 (0.64–0.95) 0.87 (0.72–1.05)
AG+GG 164, 8.8 190, 10.3 284, 8.8 0.85 (0.69–1.05) 0.99 (0.82–1.20) 0.56 0.33
glu298asp G.T GG 217, 9.7 241, 11.0 368, 9.9 0.88 (0.73–1.06) 0.98 (0.83–1.16)
GT+TT 118, 7.4 170, 10.7 243, 8.9 0.70 (0.55–0.88) 0.83 (0.67–1.04) 0.12 0.24
Heart failure
2690 C.T CC 582, 17.4 490, 14.8 697, 12.2 1.18 (1.05–1.33) 1.43 (1.28–1.59)
CT+TT 73, 17.1 72, 16.9 98, 13.6 1.02 (0.74–1.42) 1.27 (0.94–1.72) 0.40 0.47
2922 A.G AA 317, 16.5 270, 13.9 383, 11.8 1.18 (1.01–1.39) 1.39 (1.20–1.61)
AG+GG 337, 18.4 292, 16.2 412, 12.9 1.14 (0.97–1.33) 1.42 (1.24–1.65) 0.75 0.80
glu298asp G.T GG 403, 18.3 325, 14.9 448, 12.0 1.22 (1.06–1.42) 1.52 (1.33–1.74)
GT+TT 252, 16.1 237, 15.1 344, 12.8 1.07 (0.90–1.28) 1.27 (1.08–1.49) 0.25 0.09
All-cause mortality
2690 C.T CC 977, 27.4 1027, 28.8 1757, 29.1 0.95 (0.87–1.04) 0.94 (0.87–1.01)
CT+TT 135, 29.7 148, 32.4 215, 28.1 0.93 (0.73–1.17) 1.07 (0.86–1.33) 0.82 0.27
2922 A.G AA 575, 28.0 602, 28.9 1006, 29.4 0.97 (0.86–1.08) 0.95 (0.86–1.05)
AG+GG 534, 27.3 572, 29.4 963, 28.6 0.93 (0.82–1.04) 0.95 (0.86–1.06) 0.61 0.96
glu298asp G.T GG 687, 29.1 670, 28.7 1170, 29.7 1.01 (0.91–1.13) 0.98 (0.89–1.08)
GT+TT 425, 25.6 505, 30.0 798, 28.1 0.85 (0.75–0.97) 0.91 (0.81–1.03) 0.04 0.36
End-stage renal disease
2690 C.T CC 105, 3.0 102, 3.0 159, 2.7 1.02 (0.78–1.34) 1.11 (0.87–1.42)
CT+TT 7, 1.6 10, 2.3 13, 1.8 0.70 (0.27–1.85) 0.91 (0.36–2.29) 0.46 0.68
2922 A.G AA 63, 3.2 59, 3.0 92, 2.8 1.07 (0.75–1.53) 1.14 (0.82–1.57)
AG+GG 47, 2.5 54, 2.9 80, 2.5 0.85 (0.58–1.26) 1.01 (0.70–1.44) 0.40 0.63
glu298asp G.T GG 77, 3.4 73, 3.3 114, 3.0 1.04 (0.75–1.43) 1.12 (0.84–1.50)
GT+TT 35, 2.2 39, 2.4 57, 2.1 0.90 (0.57–1.43) 1.05 (0.69–1.60) 0.63 0.80
*P value: minor allele carriers combined into one group due to low numbers of events in some cells, Ho=interaction coefficient equals zero (1-degree of freedom test).
AML, amlodipine; CHD, coronary heart disease (including fatal CHD and nonfatal myocardial infarction), CHL, chlorthalidone; CI, confidence interval; LIS, lisinopril.
doi:10.1371/journal.pone.0034217.t003
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The 2786 T.C (rs2070744) polymorphism is the most studied
variant in NOS3 promoter. The C allele has been associated with
reduced promoter activity and gene transcription [42] and may
influence the risk of cardiovascular events [6,43], cardiovascular
mortality [44], and hypertension and CVD in renal allograft
recipients [45]. This SNP is in strong linkage disequilibrium with
2922A.G (In 1000 Genomes sample, R
2=0.967 in CEU,
R
2=1.00 in YRI.) It is not clear if these two variants affect the risk
of CVD through altering the NOS3 transcription and NO level.
More functional studies are needed to elucidate the mechanisms of
2690 C.T and 2922 A.G in the development of heart disease
outcomes.
In the present study, we also tested whether subjects with
different NOS3 genotypes randomized to the amlodipine had
different outcomes than their counterparts who were randomized
to lisinopril or chlorthalidone. Significant genotype6treatment
interactions were observed for stroke and all-cause mortality when
comparing amlodipine to lisinopril. CC and TT genotypes for
2690 C.T have a lower risk of stroke, while GT and TT
genotypes for glu298asp have a lower risk of all-cause mortality.
Because NOS3 glu298asp G.T genotype frequencies were not in
HW equilibrium in whites (P=0.0088), we further stratified the
white group into Hispanic whites and non-Hispanic whites and
found HW equilibrium P values were 0.49 and 0.004, respectively.
The all-cause mortality interaction ratio of hazard ratios (and P
values) for the amlodipine versus lisinopril comparison for this
variant for the combined race analysis (as reported in Table 3), the
non-Hispanic whites, and the Hispanic whites were 0.84
(P=0.04), 0.79 (P=0.04), and 0.88 (P=0.35), respectively. This
suggests the lack of HW equilibrium in the non-Hispanic white
group is not responsible for the overall pharmacogenetic
association. The randomized design of the trial minimizes
admixture as a possible confounder (i.e., degree of admixture
would be the same in treatment groups).
It has been reported that amlodipine may cause vasodilatation
through the activation of NOS3 [15]. It is known that one of the
pathways in NOS3 activation is calcium dependent. Since
amlodipine blocks the efflux of Ca, it may also deactivate NOS3
through Ca regulation. How these two actions of amlodipine on
NOS3 interact is unknown. In our analyses of CVD outcomes,
minor allele carriers tend to have more favorable outcomes when
randomized to amlodipine versus lisinopril, but not amlodipine
versus chlorthalidone, which suggests NOS3 variants may be useful
in some, but not all, antihypertensive treatment decisions.
For our suggestive pharmacogenetic findings, we used linear
regression to determine if there was an equivalent pharmacogenetic
association with change in systolic blood pressure and change in
diastolic blood pressure (DSBP, DDBP respectively; that is, blood
pressure at randomization minus blood pressure 6 months after
randomization) for the stroke/NOS3 2690 C.T and all-cause
mortality/NOS3 glu298asp G.T findings. This could suggest a
mechanistic pathway with which to explain the interaction for
outcome events. There was, however, no equivalent association
(P=0.77 and P=0.78 for DSBP and DDBP, respectively, for the
stroke findings; P=0.07 and P=0.59 for DSBP and DDBP,
respectively, for the all-cause mortality findings).
By using a large cohort of hypertensive patients, our study
suggested pharmocogenetic associations of NOS3 variants with
CVD outcomes, and demonstrated the importance of genetic
information in individualized therapy.
Because GenHAT’s parent ALLHAT population included only
older, hypertensive participants w i t ho t h e rr i s kf a c t o r sf o rC V D ,
caution must be used in generalizing these findings to younger,
healthier populations. In addition, because we interrogated the
23,529-base pair NOS3 at only 3 SNP loci,thisstudy is not a complete
evaluation of the pharmacogenetic effects of NOS3. Although it is
plausible that the polymorphisms investigated here directly influence
vascular function, variants with main or pharmacogenetic effects
cannotbeassumed causalforCVDoutcomes.Because we performed
multiple tests of pharmacogenetic effects, these findings would not
meet the strictest threshold of statistical significance if corrected for
multiple testing (e.g., Bonferroni correction: 0.05/30 tests would
equate to a P value of 0.0017).
Conclusions
Findings from this randomized, double-blind clinical trial
suggest that there are associations between NOS3 variants and
CHD and heart failure, as well as pharmacogenetic associations
for the 2690 C.T variant of NOS3 with stroke, and for the
glu298asp G.T variant with all-cause mortality when comparing
amlodipine with lisinopril. The pharmacogenetic comparison of
amlodipine versus chlorthalidone reported here suggests that
consideration of these NOS3 variants does not impinge upon
ALLHAT’s general recommendation of chlorthalidone as a first-
step therapy. However, our suggestive pharmacogenetic associa-
tions argue for future genetic and functional studies to confirm our
findings and explore the implications of NOS3 genetic variation in
hypertension treatment with respect to cardiovascular outcomes.
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